Strides Pharma Canada Inc. Balance Sheet as at March 31, 2025

				Amount in CAD
		Note No.	31-Mar-25	31-Mar-24
Α	ASSETS	INO.		
1	Non-current assets			
	(a) Other intangible assets		-	618,469
	(b) Financial assets			
	(i) Investments	1	3,803,195	3,803,195
	Total non-current assets		3,803,195	4,421,664
П	Current assets			
	(a) Financial assets			
	(i) Trade receivables	2	749,644	347,429
	(ii) Cash and cash equivalents	3	160,209	77,639
	(b) Other Current Assets	4	456,002	816,787
	Total current assets		1,365,855	1,241,855
	TOTAL ASSETS	_	5,169,050	5,663,519
В	EQUITY AND LIABILITIES			
ı	Equity			
	(a) Equity share capital	5	1,000	1,000
	(b) Share application money pending allotment		10,054,265	9,954,265
	(c) Reserves and Surplus	6	(5,684,843)	(4,863,552)
	Total Equity		4,370,422	5,091,712
II	Liabilities			
1	Current liabilities			
	(a) Financial liabilities			
	(i) Trade payables	7	628,885	541,067
	(ii) Other financial liabilities	8	136,888	16,514
	(b) Provisions	9	32,855	14,225
	Total current liabilities		798,628	571,807
	TOTAL EQUITY AND LIABILITIES	_	5,169,050	5,663,519

Strides Pharma Canada Inc. Statement of Profit And Loss for the Year Ended March 31, 2025

			Amount in CAD
Particulars	Note No.	31-Mar-25	31-Mar-24
1 Revenue from operations	10	1,284,164	1,415,126
2 Other Income	11	938,788	90,299
3 Total Revenue (1+2)	_	2,222,952	1,505,425
4 Expenses			
(a) Cost of goods sold		793,477	1,321,374
(b) Employee benefits expense	12	904,581	579,295
(c) Finance costs	13	2,496	4,634
(d) Depreciation and amortisation expense		618,469	537,459
(e) Other expenses	14	725,220	496,503
Total expenses		3,044,243	2,939,266
5 Profit / (Loss) before exceptional items and taxes (3-4)6 Exceptional Item		(821,290)	(1,433,841)
7 Profit / (Loss) before taxes (5+6)		- (024 200)	- (1, 422, 0.44)
8 Tax Expense:		(821,290)	(1,433,841)
(1) Current tax		_	_
(2) Deferred tax		-	-
Total tax expenses		-	-
9 Profit / (Loss) for the year after tax		(821,290)	(1,433,841)

STRIDES PHARMA CANADA INC. Statement of changes in Equity FOR THE YEAR ENDED MARCH 31, 2025

(A) Equity share capital

Particulars	Amount in CAD
Balance as at March 31, 2024	1,000
Changes in equity share capital during the year	-
Balance as at March 31, 2025	1,000

(B) Other equity Amount in CAD

Particulars	Share application money pending allotment	Reserves and surplus Retained earnings	Total
Balance as at March 31, 2024	9,954,265	(4,863,552)	4,790,714
Application money received during the year	100,000	-	100,000
Profit/loss for the year	-	(821,290)	(821,290)
Balance as at March 31, 2025	10,054,265	(5,684,843)	4,069,423

Strides Pharma Canada Inc. Notes forming part of financial statement

Note No.

1 Non current investments

Amount in CAD

Particulars	31-Mar-25	31-Mar-24
Pharmapar Inc	3,803,195	3,803,195
Total	3,803,195	3,803,195

2 Trade receivables

Amount in CAD

Particulars	31-Mar-25	31-Mar-24
Unsecured		
Considered good	749,644	347,429
Total	749,644	347,429

3 Cash and cash equivalents

Amount in CAD

Particulars	31-Mar-25	31-Mar-24
Balances with banks:		
In current accounts	160,209	77,639
Total	160,209	77,639

4 Other current assets

Amount in CAD

Particulars	31-Mar-25	31-Mar-24
Unsecured, considered good		
Loans and advances to Group entities	454,363	684,897
Balances with government authorities:		
- GST receivable	0	129,831
Prepaid expenses	1,639	2,059
Total	456,002	816,787

5 Share capital

Amount in CAD

Share capital		
Particulars	31-Mar-25	31-Mar-24
Issued, subscribed and fully paid-up		
Equity share capital	1,000	1,000
Total	1,000	1,000

6 Reserves and surplus

Amount in CAD

Particulars	31-Mar-25	31-Mar-24
Share Application money Pending Allotment	10,054,265	9,954,265
Add: Addition during the year	-	-
Share Application money Pending Allotment	10,054,265	9,954,265
Surplus in statement of profit and loss		
Opening balance	(4,863,552)	(2,936,885)
Add: Profit / (Loss) for the year	(821,290)	(1,926,667)
Closing balance	(5,684,843)	(4,863,552)
Total	4,369,422	5,090,712

Strides Pharma Canada Inc.

Notes forming part of financial statement

Note No.

7 Trade payables

Amount in CAD

Particulars	31-Mar-25	31-Mar-24
Trade payable	628,885	541,067
Total	628,885	541,067.41

8 Other Current financial Liabilities

Amount in CAD

Particulars	31-Mar-25	31-Mar-24
Payable to group entities		
Payable to employee (salary)	29,641	(9,474)
Other payables:		
- Statutory remittances	107,248	25,988
Total	136,888	16,514

9 Provisions

Amount in CAD

Particulars	31-Mar-25	31-Mar-24
Provision for expenses	32,854	14,224
Total	32,854	14,224

10 Revenue from operations

Amount in CAD

Particulars	31-Mar-25	31-Mar-24
Sale of product and services	1,284,164	1,415,126
Total	1,284,164	1,415,126

11 Other Income

Amount in CAD

Particulars	31-Mar-25	31-Mar-24
Other Income	938,788	-
Exchange fluctuation gain - Not realized	-	44,515
Interest income	-	45,783
Total	938,788	90,299

12 Employee benefit expenses

Amount in CAD

Particulars	31-Mar-25	31-Mar-24
Salaries and wages	904,581	579,295
Total	904,581	579,295

13 Finance cost

Amount in CAD

Particulars	31-Mar-25	31-Mar-24
Finance Cost	2,496	4,634
Total	2,496	4,634

Strides Pharma Canada Inc. Notes forming part of financial statement

14 Other expenses

Amount in CAD

Particulars	31-Mar-25	31-Mar-24
Consumables	25,339	41,733
Rent	5,209	-
Coversion & processing charges	12,000	16,944
Rates & taxes	411,955	290,224
Repairs & Maintenance	430	306
Courier Charges	-	386
Insurance	16,032	12,759
General expenses	-	3,333
Printing & stationery	-	1,201
Director Sitting Fess	7,000	7,000
Exchange fluctuation loss	162,883	
Professional fees & Legal fees	84,372	93,738
Provision for doubtful debts	-	28,880
Total	725,220	496,503